Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells

Rita Garamvölgyi, J. Dobos, Anna Sipos, Sándor Boros, Eszter Illyés, Ferenc Baska, László Kékesi, István Szabadkai, Csaba Szántai-Kis, G. Kéri, L. Őrfi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Melanoma is an aggressive form of skin cancer and it is generally associated with poor prognosis in patients with late-stage disease. Due to the increasing occurrence of melanoma, there is a need for the development of novel therapies. A new series of diarylamide and diarylurea derivatives containing imidazo[1,2-a]pyridine or imidazo[1,2-a]pyrazine scaffold was designed and synthesized to investigate their in vitro efficacy against the A375P human melanoma cell line. We found several compounds expressing submicromolar IC50 values against the A375P cells, from which 15d, 17e, 18c, 18h, 18i demonstrated the highest potencies with IC50 below 0.06 μM.

Original languageEnglish
Pages (from-to)623-643
Number of pages21
JournalEuropean Journal of Medicinal Chemistry
Volume108
DOIs
Publication statusPublished - Jan 27 2016

Fingerprint

Scaffolds
Melanoma
Skin
Cells
Derivatives
Inhibitory Concentration 50
Skin Neoplasms
Cell Line
imidazo(1,2-a)pyridine
imidazo(1,2-a)pyrazine
Therapeutics
In Vitro Techniques

Keywords

  • A375P
  • Antiproliferative activity
  • Diarylamide
  • Diarylurea
  • Imidazo[1,2-a]pyrazine
  • Imidazo[1,2-a]pyridine
  • Melanoma

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells. / Garamvölgyi, Rita; Dobos, J.; Sipos, Anna; Boros, Sándor; Illyés, Eszter; Baska, Ferenc; Kékesi, László; Szabadkai, István; Szántai-Kis, Csaba; Kéri, G.; Őrfi, L.

In: European Journal of Medicinal Chemistry, Vol. 108, 27.01.2016, p. 623-643.

Research output: Contribution to journalArticle

Garamvölgyi, Rita ; Dobos, J. ; Sipos, Anna ; Boros, Sándor ; Illyés, Eszter ; Baska, Ferenc ; Kékesi, László ; Szabadkai, István ; Szántai-Kis, Csaba ; Kéri, G. ; Őrfi, L. / Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells. In: European Journal of Medicinal Chemistry. 2016 ; Vol. 108. pp. 623-643.
@article{97106bf1299d4de0ad95ad49837794f6,
title = "Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells",
abstract = "Melanoma is an aggressive form of skin cancer and it is generally associated with poor prognosis in patients with late-stage disease. Due to the increasing occurrence of melanoma, there is a need for the development of novel therapies. A new series of diarylamide and diarylurea derivatives containing imidazo[1,2-a]pyridine or imidazo[1,2-a]pyrazine scaffold was designed and synthesized to investigate their in vitro efficacy against the A375P human melanoma cell line. We found several compounds expressing submicromolar IC50 values against the A375P cells, from which 15d, 17e, 18c, 18h, 18i demonstrated the highest potencies with IC50 below 0.06 μM.",
keywords = "A375P, Antiproliferative activity, Diarylamide, Diarylurea, Imidazo[1,2-a]pyrazine, Imidazo[1,2-a]pyridine, Melanoma",
author = "Rita Garamv{\"o}lgyi and J. Dobos and Anna Sipos and S{\'a}ndor Boros and Eszter Illy{\'e}s and Ferenc Baska and L{\'a}szl{\'o} K{\'e}kesi and Istv{\'a}n Szabadkai and Csaba Sz{\'a}ntai-Kis and G. K{\'e}ri and L. Őrfi",
year = "2016",
month = "1",
day = "27",
doi = "10.1016/j.ejmech.2015.12.001",
language = "English",
volume = "108",
pages = "623--643",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells

AU - Garamvölgyi, Rita

AU - Dobos, J.

AU - Sipos, Anna

AU - Boros, Sándor

AU - Illyés, Eszter

AU - Baska, Ferenc

AU - Kékesi, László

AU - Szabadkai, István

AU - Szántai-Kis, Csaba

AU - Kéri, G.

AU - Őrfi, L.

PY - 2016/1/27

Y1 - 2016/1/27

N2 - Melanoma is an aggressive form of skin cancer and it is generally associated with poor prognosis in patients with late-stage disease. Due to the increasing occurrence of melanoma, there is a need for the development of novel therapies. A new series of diarylamide and diarylurea derivatives containing imidazo[1,2-a]pyridine or imidazo[1,2-a]pyrazine scaffold was designed and synthesized to investigate their in vitro efficacy against the A375P human melanoma cell line. We found several compounds expressing submicromolar IC50 values against the A375P cells, from which 15d, 17e, 18c, 18h, 18i demonstrated the highest potencies with IC50 below 0.06 μM.

AB - Melanoma is an aggressive form of skin cancer and it is generally associated with poor prognosis in patients with late-stage disease. Due to the increasing occurrence of melanoma, there is a need for the development of novel therapies. A new series of diarylamide and diarylurea derivatives containing imidazo[1,2-a]pyridine or imidazo[1,2-a]pyrazine scaffold was designed and synthesized to investigate their in vitro efficacy against the A375P human melanoma cell line. We found several compounds expressing submicromolar IC50 values against the A375P cells, from which 15d, 17e, 18c, 18h, 18i demonstrated the highest potencies with IC50 below 0.06 μM.

KW - A375P

KW - Antiproliferative activity

KW - Diarylamide

KW - Diarylurea

KW - Imidazo[1,2-a]pyrazine

KW - Imidazo[1,2-a]pyridine

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=84951335524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951335524&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2015.12.001

DO - 10.1016/j.ejmech.2015.12.001

M3 - Article

C2 - 26724730

AN - SCOPUS:84951335524

VL - 108

SP - 623

EP - 643

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -